You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Orlistat with diet was effective and safe for weight loss and coronary risk reduction in obesity

https://doi.org/10.1136/ebm.6.2.54

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2000) J Intern Med 248, 245. Lindgärde F, on behalf of the Orlistat Swedish Multimorbidity Study Group.. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.. Sep;. :. –54.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: What is the effectiveness of orlistat for weight loss and coronary artery disease risk factor reduction in people who are obese and have ≥1 coronary risk factor?

    Design

    Randomised (unclear allocation concealment*), blinded (patients, outcome assessors),* placebo controlled trial with 1 year follow up.

    Setting

    33 primary care centres in Sweden.

    Patients

    376 patients between 18 and 75 years of age (mean age 53 y, 64% women) who had a body mass index between 28 and 38 kg/m2. Patients had to have ≥1 of the following: fasting serum glucose concentration ≥6.7 mmol/l or type-2 diabetes mellitus treated with sulfonylurea or metformin (not insulin); cholesterol concentration ≥6.5 mmol/l or low density lipoprotein (LDL) cholesterol concentration ≥4.2 mmol/l on ≥2 occasions, or lipid lowering medication; or diastolic blood pressure concentration ≥90 mm Hg on ≥2 …

    View Full Text

    Footnotes

    • Source of funding: Roche AB, Stockholm, Sweden.

    • For correspondence: Dr F Lindgärde, Department of Vascular Disease, Malmö University Hospital, University of Lund, 20502 Malmö, Sweden. Fax + 46 4019 4617.

    • ↵* See glossary.